Short answer
Journey Medical Corp (DERM) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). September 30, 2026 quarter results and corporate update announced by Journey Medical Corporation.
Journey Medical Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- September 30, 2026 quarter results and corporate update announced by Journey Medical Corporation
- Financial details and management commentary contained in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue $19.0M, up 8% year over year, signaling continued commercial momentum
- Emrosi revenue $9.0M, up 84%, with approximately 40,000 prescriptions and stronger reimbursement trends
- Gross margin improved to 69% from 67%, supporting operating leverage despite higher selling expenses
- GAAP net loss narrowed to $1.3M, or $(0.05) per share, while Adjusted EBITDA reached $3.5M
- Cash $22.3M versus $24.1M at December 31, 2025, with current term-loan obligations of $7.5M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Journey Medical Corp 8-K filings
Get the next DERM 8-K as it lands
Follow DERM for push alerts, or ask the research agent what this filing means.